First Overseas Supply Milestone Achieved Through Global Network Collaboration

Sigimedtech, a company specializing in the research and manufacturing of orthopedic and dental implants, announced on June 5 that it has signed an exclusive supply agreement with DePuy Synthes, a global orthopedic solutions company, for 'Novosis Trauma' in the Malaysian market.

'Novosis Trauma' product. Sigimedtec

'Novosis Trauma' product. Sigimedtec

View original image

Under this agreement, DePuy Synthes will be responsible for the exclusive distribution and sales of Novosis Trauma products in Malaysia. Sigimedtech will support the expansion of its local market presence by providing a stable supply and production system.


Novosis Trauma is a bone regeneration solution that combines a hydroxyapatite-based synthetic bone matrix with recombinant human bone morphogenetic protein-2 (rhBMP-2). The product is designed to induce bone formation in cases of traumatic fractures and bone defects. It is used for bone union and regeneration in orthopedic trauma treatment and is expanding its potential applications in the field of complex bone defect treatment.


This contract is particularly significant as it marks Sigimedtech's first overseas supply case based on a strategic collaboration with a global healthcare company. Through this agreement, Sigimedtech has been able to demonstrate the competitiveness of its rhBMP-2-based bone regeneration technology and its potential for global commercialization.


Malaysia is considered one of the fastest-growing markets in Southeast Asia for orthopedic and trauma care. The company plans to expand product accessibility and market recognition by leveraging its partner's local hospital network and distribution capabilities. Furthermore, starting with this agreement, Sigimedtech aims to expand its supply focus to Asian and Oceania markets, while also considering additional collaborations in the Middle East and other global markets in the future.


Currently, the two companies are coordinating local sales forecasts and supply schedules, and will gradually increase the supply volume in response to market conditions and rising demand.



Yoo Hyunseung, CEO of Sigimedtech, stated, "This agreement is a meaningful example of verifying the product competitiveness and overseas commercialization potential of Novosis Trauma through collaboration with a global healthcare company. Based on our partner's global network and Sigimedtech's bone regeneration technology, we will expand our overseas supply base and strengthen our competitiveness in the global orthopedic trauma care market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing